Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?

Palmer, Joshua D.; Bhamidipati, Deepak; Song, Andrew; Eldredge-Hindy, Harriet; Siglin, Joshua; Dan, Tu; Champ, Colin E.; Zhang, Isabella; Bar‐Ad, Voichita; Kim, Lyndon; Glass, Jon; Evans, James J.; Andrews, David W.; Werner‐Wasik, Maria; Shi, Wenyin

doi:10.1007/s11060-018-2989-z

Cited by 26 publications

(23 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations are corroborated by data from a randomized phase II trial of APG101 (a CD95 ligand-binding fusion protein) plus reirradiation versus reirradiation only in progressive glioblastoma (a median overall survival of 11.5 months in each group) [134]. A recent retrospective study suggests that a combination of bevacizumab and re-irradiation (fractionated stereotactic RT) for progressive or recurrent high-grade gliomas may moderately increase median overall survival (>13 months from recurrence) [135]. A randomized phase II trial of concurrent bevacizumab and re-irradiation versus bevacizumab only for recurrent glioblastoma patients is ongoing (NCT01730950).…”

Section: No Molecularly Targeted Drug(s) For Glioblastoma On the Hmentioning

confidence: 82%

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

Stepanenko

Chekhonin

2018

Cancers

View full text Add to dashboard Cite

To date, no targeted drugs, antibodies or combinations of chemotherapeutics have been demonstrated to be more efficient than temozolomide, or to increase efficacy of standard therapy (surgery, radiotherapy, temozolomide, steroid dexamethasone). According to recent phase III trials, standard therapy may ensure a median overall survival of up to 18–20 months for adult patients with newly diagnosed glioblastoma. These data explain a failure of positive non-controlled phase II trials to predict positive phase III trials and should result in revision of the landmark Stupp trial as a historical control for median overall survival in non-controlled trials. A high rate of failures in clinical trials and a lack of effective chemotherapy on the horizon fostered the development of conceptually distinct therapeutic approaches: dendritic cell/peptide immunotherapy, chimeric antigen receptor (CAR) T-cell therapy and oncolytic virotherapy. Recent early phase trials with the recombinant adenovirus DNX-2401 (Ad5-delta24-RGD), polio-rhinovirus chimera (PVSRIPO), parvovirus H-1 (ParvOryx), Toca 511 retroviral vector with 5-fluorocytosine, heat shock protein-peptide complex-96 (HSPPC-96) and dendritic cell vaccines, including DCVax-L vaccine, demonstrated that subsets of patients with glioblastoma/glioma may benefit from oncolytic virotherapy/immunotherapy (>3 years of survival after treatment). However, large controlled trials are required to prove efficacy of next-generation immunotherapeutics and oncolytic vectors.

show abstract

Section: No Molecularly Targeted Drug(s) For Glioblastoma On the Hmentioning

confidence: 82%

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

Stepanenko

Chekhonin

2018

Cancers

View full text Add to dashboard Cite

show abstract

“…1 , 2 Despite standard therapy including surgery, chemo- and radiotherapy have been widely adopted, the average survival time is only about 15 months, whereas the 5-year survival rate is only 4–5%, 3 – 5 Irrespective of the current aggressive and multi-model first-line approaches of diagnosis and treatment, recurrence of glioblastoma (GBM) is practically inevitable, with an average time of recurrence is less than 10 months. 2 , 6 – 8 Various treatments modalities are utilized, including repeat resection, irradiation, and systemic agents; however, the prognosis for these patients remains discouraging. The need for more innovative therapeutic strategies to expedite recurrent glioma therapeutics is imperative.…”

Section: Introductionmentioning

confidence: 99%

<p>Local Delivery of Minocycline and Vorinostat Targets the Tumor Microenvironment to Inhibit the Recurrence of Glioma</p>

Zhao

Jia

Wang

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Postoperative recurrence is the main reason for poor clinical outcomes in glioma patients, so preventing tumor recurrence is crucial in the management of gliomas. Methods: In this study, the expression of matrix metalloproteinases (MMPs) in normal tissues was detected via RNA-seq analysis. Glioma cases from the public databases (The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA)) were included in this study. The hydrogel contains minocycline (Mino) and vorinostat (Vor) (G/Mino+Vor) was formed under 365 nm when the photoinitiator was added. High-performance liquid chromatography (HPLC) was used to assess the release of drugs in the G/Mino+Vor hydrogel. An MTT assay was used to explore the biosecurity of GelMA. Immunohistochemistry, ELISA, and TUNEL assays were used to demonstrate the antitumor effect of the G/Mino +Vor hydrogel. Results: We successfully developed a G/Mino+Vor hydrogel. The experiments in vitro and in vivo confirmed the MMPs-responsive delivery of minocycline and vorinostat in hydrogel and the anti-glioma effect on an incomplete tumor operation model, which indicated that the G/Mino+Vor hydrogel effectively inhibited the recurrence of glioma after surgery. Conclusion: In summary, the G/Mino+Vor hydrogel could continuously release drugs and improve the therapy effects against recurrent glioma.

show abstract

“…Irrespective of the current aggressive and multi-modal rst-line approaches at diagnosis and treatment, recurrence in glioblastoma (GBM) is practically inevitable with average time to recurrence is less than 10 months (2,(6)(7)(8). Various treatment modalities are utilized including repeat resection, irradiation and systemic agents, yet prognosis for these patients remains discouraging.…”

Section: Introductionmentioning

confidence: 99%

Local Delivery of Minocycline and Vorinostat Act Synergistically to Inhibit Recurrence of Gliomas

Zhao

Jia

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background:Postoperative recurrence is the main reason of poor clinical consequences in glioma patients, so preventing recurrence of tumors is crucial in management of gliomas. Methods:In this study, the expression of matrix metalloproteinases (MMPs)in tissues from normal were detected by using RNA-seq analysis.Glioma cases from the public databases (The Cancer Genome Atlas (TCGA), The Chinese Glioma Genome Atlas(CGGA), Betastasis) were included in this study.The hydrogelcontains minocycline (Mino) and vorinostat (Vor)(G/Mino + Vor) was formed under 365 nm when photoinitiator was added in. High Performance Liquid Chromatography (HPLC) assay was used to assessed the release of drugs in G/Mino + Vor hydrogel. MTT assay was used to explore the biosecurity of GelMA. Immunohistochemistry assay, ELISA assay, Tunel assay were used to demonstrate the antitumor effect of G/Mino + Vor hydrogel.Results:We developed G/Mino + Vor hydrogel successfully. Thenthe experiment in vitro and in vivo confirmed MMPs-responsive delivery of minocycline and vorinostat in hydrogel and the anti-glioma effect on incomplete tumor operation model, which indicated that G/Mino + Vor hydrogel effectively inhibited the recurrence of glioma after surgery.Conclusions: In summary, G/Mino + Vor hydrogel could continuous release minocycline and vorinostat in surgical cavity for inhibiting local recurrence of glioma after operation.

show abstract

Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?

Cited by 26 publications

References 17 publications

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

<p>Local Delivery of Minocycline and Vorinostat Targets the Tumor Microenvironment to Inhibit the Recurrence of Glioma</p>

Local Delivery of Minocycline and Vorinostat Act Synergistically to Inhibit Recurrence of Gliomas

Contact Info

Product

Resources

About